Seon Ah Lim

Title: Seon Ah Lim: Innovator in Cell Therapy

Introduction

Seon Ah Lim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cell therapy, particularly in the development of methods for expanding natural killer cells. With a total of 5 patents, his work is pivotal in advancing therapeutic techniques for cancer treatment.

Latest Patents

One of his latest patents is an "Expansion culture method for human-derived natural killer cells by using HDAC inhibitor." This invention focuses on a method that enhances the viability and production yield of natural killer cells during in vitro expansion culture. By treating these cells with an HDAC inhibitor, the method effectively prevents cell death, making it a valuable approach for cell therapy applications.

Another notable patent is related to "IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer." This invention involves a heterodimeric Fc-fused protein that significantly increases the in vivo half-life of IL-21, which is crucial for therapeutic applications.

Career Highlights

Seon Ah Lim has worked with esteemed institutions such as Korea University Research and Business Foundation and Ajou University Industry-Academic Cooperation Foundation. His experience in these organizations has allowed him to collaborate on innovative research projects that push the boundaries of cell therapy.

Collaborations

Some of his notable coworkers include Kyung-Mi Lee and Cassian Yee. Their collaborative efforts have contributed to the advancements in the field of cell therapy and related research.

Conclusion

Seon Ah Lim's innovative work in expanding natural killer cells and developing advanced therapeutic proteins showcases his dedication to improving cancer treatment methodologies. His contributions are essential in the ongoing quest for effective cell therapies.